• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Comparison of intravenous and oral verapamil dosing.

作者信息

Reiter M J, Shand D G, Pritchett E L

出版信息

Clin Pharmacol Ther. 1982 Dec;32(6):711-20. doi: 10.1038/clpt.1982.227.

DOI:10.1038/clpt.1982.227
PMID:7140136
Abstract

To compare the effects of intravenous and oral verapamil we examined the prolongation of the PR interval in 11 patients after (1) a single 10 mg IV bolus given over 2 min, (2) a single oral dose of 120 mg, and (3) a sustained concentration-maintaining infusion. Maximal PR interval prolongation was delayed relative to peak plasma verapamil concentration in all patients after the bolus and in seven of 11 patients after oral dosing. In all 11 patients oral verapamil was less potent than a single intravenous bolus of verapamil; the plasma verapamil concentration corresponding to a 10% prolongation of the PR was 39.5 +/- 21.7 ng/ml after the bolus and 146.3 +/- 75.1 ng/ml after the oral dose (P = 0.001). However, there was no such difference between oral verapamil and an infusion in six patients. The plasma verapamil concentration corresponding to a 10% PR prolongation was 35.7 +/- 24 ng/ml after the bolus, 132.5 +/- 80.8 ng/ml after the oral dose, and 85.2 +/- 29.9 ng/ml after the infusion. Maximum PR prolongation (drug efficacy) was comparable for the three methods of administration. There was no evidence of tachyphalaxis during prolonged infusions. We conclude that both oral doses and infusions of verapamil are less potent then bolus doses, but that drug efficacy at the concentrations reached is equivalent for the three. Plasma verapamil concentrations determined after bolus doses appear to underestimate effective plasma concentration when the drug is given by the oral or infusion methods.

摘要

相似文献

1
Comparison of intravenous and oral verapamil dosing.
Clin Pharmacol Ther. 1982 Dec;32(6):711-20. doi: 10.1038/clpt.1982.227.
2
Pharmacokinetics of verapamil: experience with a sustained intravenous infusion regimen.维拉帕米的药代动力学:持续静脉输注方案的经验
Am J Cardiol. 1982 Oct;50(4):716-21. doi: 10.1016/0002-9149(82)91224-3.
3
Prediction of steady-state verapamil plasma concentrations in children and adults.
Clin Pharmacol Ther. 1982 Aug;32(2):172-81. doi: 10.1038/clpt.1982.144.
4
R-verapamil: pharmacokinetics and effects on PR interval, blood pressure and heart rate.R-维拉帕米:药代动力学及其对PR间期、血压和心率的影响
Br J Clin Pharmacol. 1993 Aug;36(2):93-8. doi: 10.1111/j.1365-2125.1993.tb04202.x.
5
The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses.
Clin Pharmacol Ther. 1982 Apr;31(4):418-26. doi: 10.1038/clpt.1982.54.
6
Effects of d,l-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism.消旋维拉帕米对房室传导的影响及其立体选择性首过代谢的关系。
Clin Pharmacol Ther. 1985 Jul;38(1):71-6. doi: 10.1038/clpt.1985.137.
7
Verapamil disposition and cardiovascular effects in elderly patients after single intravenous and oral doses.老年患者单次静脉注射和口服维拉帕米后的药物处置及心血管效应
Cardiovasc Drugs Ther. 1989 Jun;3(3):417-25. doi: 10.1007/BF01858113.
8
Verapamil disposition kinetics in chronic atrial fibrillation.维拉帕米在慢性心房颤动中的处置动力学
Clin Pharmacol Ther. 1981 Jul;30(1):44-51. doi: 10.1038/clpt.1981.125.
9
Effects of verapamil on P-R-intervals in relation to verapamil plasma levels following single I.V. and oral administration and during chronic treatment.静脉注射和口服维拉帕米单次给药后及长期治疗期间,维拉帕米对P-R间期与维拉帕米血药浓度关系的影响。
Klin Wochenschr. 1980 Sep 15;58(18):919-25. doi: 10.1007/BF01477049.
10
The pharmacology of verapamil. I. Elimination kinetics in dogs and correlation of plasma levels with effect on the eletrocardiogram.
J Pharmacol Exp Ther. 1977 Jul;202(1):38-44.

引用本文的文献

1
Predicting QRS and PR interval prolongations in humans using nonclinical data.使用非临床数据预测人体 QRS 和 PR 间期延长。
Br J Pharmacol. 2017 Oct;174(19):3268-3283. doi: 10.1111/bph.13940. Epub 2017 Aug 24.
2
Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.理解药代动力学/药效动力学关系中的滞后环难题。
J Pharm Pharm Sci. 2014;17(1):34-91.
3
New mathematical implementation of generalized pharmacodynamic models: method and clinical evaluation.
J Pharmacokinet Biopharm. 1997 Jun;25(3):313-48. doi: 10.1023/a:1025723725312.
4
Individual variation in first-pass metabolism.首过代谢的个体差异。
Clin Pharmacokinet. 1993 Oct;25(4):300-28. doi: 10.2165/00003088-199325040-00005.
5
Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration.静脉注射后(+)-、(-)-和(±)-维拉帕米的药代动力学
Br J Clin Pharmacol. 1984 Apr;17(4):453-8. doi: 10.1111/j.1365-2125.1984.tb02371.x.
6
Pharmacokinetic and pharmacodynamic considerations in drug therapy of cardiac emergencies.心脏急症药物治疗中的药代动力学和药效学考量
Clin Pharmacokinet. 1984 Jul-Aug;9(4):273-308. doi: 10.2165/00003088-198409040-00001.
7
First-pass elimination. Basic concepts and clinical consequences.首过消除。基本概念及临床后果。
Clin Pharmacokinet. 1984 Jan-Feb;9(1):1-25. doi: 10.2165/00003088-198409010-00001.
8
Plasma levels and myocardial content of verapamil, norverapamil and two N-dealkyl-metabolites in man.
Eur J Clin Pharmacol. 1985;28(6):653-7. doi: 10.1007/BF00607910.
9
Multiple sclerosis: failure of treatment with verapamil in a pilot trial.
J Neurol. 1986 Feb;233(1):59-60. doi: 10.1007/BF00313996.
10
Pharmacokinetics of sustained-release verapamil after a single administration and at steady state.单次给药及稳态下缓释维拉帕米的药代动力学
Eur J Drug Metab Pharmacokinet. 1985 Apr-Jun;10(2):133-8. doi: 10.1007/BF03189707.